Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Thermo Fisher Scientific Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

The financial data over the five-year period reveals distinct trends in the company’s profitability and leverage metrics.

Return on Assets (ROA)
The ROA exhibits a declining trend from 9.23% in 2020 to a low of 6.07% in 2023, followed by a slight recovery to 6.51% in 2024. This overall decrease indicates a gradual reduction in asset efficiency, suggesting that the company generated lower returns from its asset base over time, despite a modest improvement in the final year.
Financial Leverage
Financial leverage peaked in 2021 at 2.33 but has steadily declined each year thereafter, reaching 1.96 in 2024. This pattern implies that the company has been reducing its reliance on debt relative to equity in recent years, possibly aiming to strengthen its balance sheet and reduce financial risk.
Return on Equity (ROE)
ROE appears to have decreased markedly from 18.47% in 2020 to 12.78% in 2024, with the most significant drop occurring between 2021 and 2023. The decline in ROE, combined with lower financial leverage, indicates that the company is generating lower returns for shareholders, potentially as a result of decreased profitability and reduced leverage amplification effects.

In summary, the data suggests a gradual decline in profitability metrics over the period, accompanied by a conscious reduction in financial leverage. The company appears to have prioritized decreasing its debt exposure, which may have contributed to diminished equity returns. The slight uptick in ROA in the most recent year could signal early signs of operational improvement.


Three-Component Disaggregation of ROE

Thermo Fisher Scientific Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Net Profit Margin
The net profit margin exhibited a declining trend from 19.79% in 2020 to 13.99% in 2023, indicating a decrease in profitability relative to sales over this period. However, a slight recovery to 14.77% is observed in 2024, suggesting a modest improvement in profit efficiency after consecutive annual declines.
Asset Turnover
The asset turnover ratio fluctuated marginally between 0.41 and 0.47 over the five-year period. It decreased from 0.47 in 2020 to 0.41 in 2021, then rose to 0.46 in 2022 before slightly tapering off to 0.44 by 2024. Overall, the ratio remained relatively stable, indicating consistent efficiency in generating revenues from assets.
Financial Leverage
Financial leverage showed a gradual reduction from a ratio of 2.00 in 2020 to 1.96 in 2024, with a peak of 2.33 in 2021. This trend reflects a slight decrease in the use of debt financing relative to equity over the observed years, possibly indicating a more conservative capital structure.
Return on Equity (ROE)
The return on equity demonstrated a downward trend, declining from 18.47% in 2020 to 12.78% in 2024. This decrease aligns with the reduction in both net profit margin and financial leverage, suggesting diminished profitability and efficiency in generating returns for shareholders.

Five-Component Disaggregation of ROE

Thermo Fisher Scientific Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2024 = × × × ×
Dec 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×
Dec 31, 2020 = × × × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Tax Burden
The tax burden ratio exhibited a generally increasing trend from 0.88 in 2020 to a peak of 0.95 in 2023, followed by a slight decline to 0.91 in 2024. This indicates a somewhat higher portion of income retained after tax in the middle years, with a slight reduction in tax efficiency in the final year observed.
Interest Burden
The interest burden ratio remained relatively stable around 0.93-0.94 in 2020 and 2021, but experienced a notable decline to 0.82 in 2023, before slightly improving to 0.83 in 2024. This pattern suggests an increased interest expense impact during the later years, which could be indicative of higher debt servicing costs or changes in financing structure.
EBIT Margin
The EBIT margin showed a declining trend from 24.14% in 2020 to 17.86% in 2023, with a modest recovery to 19.55% in 2024. This downward trend through most of the period points to a decrease in operating profitability, though the slight rebound in the final year may reflect efficiency improvements or cost control measures.
Asset Turnover
Asset turnover ratios fluctuated slightly around the 0.41 to 0.47 range, starting at 0.47 in 2020, dipping to 0.41 in 2021, and then stabilizing around 0.43 to 0.46 thereafter. This stable pattern suggests that the efficiency of asset utilization in generating revenue remained relatively constant without significant improvements or deteriorations.
Financial Leverage
Financial leverage trended downward from 2.00 in 2020 to 1.96 in 2024, passing through a peak of 2.33 in 2021. This indicates a gradual reduction in reliance on debt financing over the period, potentially reflecting efforts to strengthen the equity base or reduce financial risk.
Return on Equity (ROE)
The return on equity demonstrated a declining trajectory from 18.47% in 2020 to 12.78% in 2024, with the most significant drops occurring between 2021 and 2023. This decline in ROE is aligned with the observed decreases in EBIT margin and interest burden deterioration, indicating reduced profitability and efficiency in generating shareholder returns over time.

Two-Component Disaggregation of ROA

Thermo Fisher Scientific Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Net Profit Margin
The net profit margin exhibited a declining trend from 19.79% in 2020 to 13.99% in 2023, representing a significant decrease in profitability. However, there is a slight improvement observed in 2024, with the margin rising to 14.77%, indicating a potential stabilization or modest recovery in profit retention relative to revenue.
Asset Turnover
The asset turnover ratio fluctuated moderately during the period. It started at 0.47 in 2020, declined to a low of 0.41 in 2021, then recovered to 0.46 in 2022. A slight decrease occurred again in 2023 to 0.43, followed by a small increase to 0.44 in 2024. Overall, the ratio suggests relatively stable efficiency in using assets to generate revenue, with minor variations.
Return on Assets (ROA)
Return on Assets showed a downward trajectory from 9.23% in 2020 to 6.07% in 2023, indicating diminishing effectiveness in asset utilization to generate profits. In 2024, there was a marginal increase to 6.51%, suggesting an early sign of improvement but still below initial levels observed in 2020.

Four-Component Disaggregation of ROA

Thermo Fisher Scientific Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2024 = × × ×
Dec 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Dec 31, 2021 = × × ×
Dec 31, 2020 = × × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Tax Burden
The tax burden ratio remained relatively stable over the five-year period. Starting at 0.88 in 2020, it decreased slightly to 0.87 in 2021, then increased to a peak of 0.95 in 2023 before moderating to 0.91 in 2024. This indicates some volatility but generally reflects a consistent proportion of pre-tax income retained after taxes.
Interest Burden
The interest burden showed a declining trend starting from 0.93 in 2020 and rising marginally to 0.94 in 2021, followed by a more notable decrease to 0.91 in 2022 and then a sharper decline to 0.82 in 2023. It slightly improved to 0.83 in 2024. This suggests increasing interest expenses relative to earnings before interest and taxes, which could indicate higher debt costs or leverage.
EBIT Margin
The EBIT margin experienced a downward trend from 24.14% in 2020 to a low of 17.86% in 2023. However, it rebounded somewhat to 19.55% in 2024. Despite the recovery, the margin remained lower than the starting point, signaling potential pressure on operational profitability over the years.
Asset Turnover
Asset turnover fluctuated moderately within a narrow range. It began at 0.47 in 2020, dipped to 0.41 in 2021, then rose to 0.46 in 2022 before slightly decreasing to 0.43 in 2023 and marginally increasing to 0.44 in 2024. This pattern indicates a relatively stable efficiency in using assets to generate sales, without significant improvement or deterioration.
Return on Assets (ROA)
The return on assets trend showed a decrease from 9.23% in 2020 to 6.07% in 2023, reflecting diminishing overall profitability relative to asset base. In 2024, the ROA experienced a minor recovery to 6.51%. The declining trend aligns with the decreases observed in both EBIT margin and interest burden and highlights challenges in maintaining asset profitability.

Disaggregation of Net Profit Margin

Thermo Fisher Scientific Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Tax Burden
The tax burden ratio exhibited a generally positive trend from 2020 to 2023, increasing from 0.88 to 0.95, which suggests an improving tax efficiency. However, there was a slight decline to 0.91 in 2024, indicating a minor setback in this area.
Interest Burden
The interest burden ratio remained relatively stable around 0.91 to 0.94 during 2020 and 2021, but then experienced a marked decline to 0.82 in 2023, which persisted slightly better at 0.83 in 2024. This reduction may reflect increased interest expenses or changes in debt structure impacting earnings before interest and taxes.
EBIT Margin
The EBIT margin demonstrated a declining trend from 24.14% in 2020 to a low of 17.86% in 2023, with a slight recovery to 19.55% in 2024. This pattern indicates diminishing operational profitability over the period, with some improvement towards the end.
Net Profit Margin
The net profit margin followed a similar downward trajectory, starting at 19.79% in 2020 and dropping to 13.99% in 2023, before rising marginally to 14.77% in 2024. This decline reflects reduced overall profitability, potentially influenced by rising costs, lower operational margins, or other expenses.